Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: This study sought to explore whether generalised joint hypermobility (GJH, a common marker of variant connective tissue) was a risk factor for self-reported non-recovery from COVID-19 infection.
Design: Prospective observational study.
Setting: COVID Symptom Study Biobank (https://cssbiobank.com/) UK.
Participants: Participants were surveyed in August 2022. 3064 (81.4%) reported at least one infection with COVID-19. These individuals self-reported on recovery and completed a self-report questionnaire to detect GJH (Hakim and Grahame 5-part questionnaire, 5PQ).
Main Outcome Measures: The primary outcome was the presence of self-reported non-recovery from COVID-19 infection at the time of the survey. Additional outcomes included scores on 5PQ and self-reported fatigue level (Chalder Fatigue Scale).
Results: The presence of GJH was not specifically associated with reported COVID-19 infection risk per se. However, it was significantly associated with non-recovery from COVID-19 (OR 1.43 (95% CI 1.20 to 1.70)). This association remained after sequential models adjusting for age, sex, ethnic group, education level and index of multiple deprivation (OR 1.33 (95% CI 1.10 to 1.61)) and further adjustment for vaccination status and number of vaccinations (OR 1.33 (95% CI 1.10 to 1.60)). Additionally, including in a model adjusting for all covariates, hypermobility significantly predicted higher fatigue levels (B=0.95, SE=0.25, t=3.77, SE, p=0.002). Fatigue levels mediated the link between GJH and non-recovery from COVID-19 (estimate of indirect effect=0.18, 95% bootstrapped CI 0.08 to 0.29).
Conclusions: Individuals with GJH were approximately 30% more likely not to have recovered fully from COVID-19 infection at the time of the questionnaire, and this predicted the fatigue level. This observation is clinically important through its potential impact for understanding and identifying sub-phenotypes of long COVID for screening and personalised targeted interventions. More generally, greater awareness of GJH and its extra-articular associations is needed for effective patient stratification and implementation of personalised medicine.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812800 | PMC |
| http://dx.doi.org/10.1136/bmjph-2023-000478 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarkers and early-onset acute kidney injury in critically ill COVID-19 patients, a prospective monocentric observational study.
BMC Nephrol
July 2025
CHU Clermont-Ferrand, Service de Réanimation Médicale, Clermont- Ferrand, France.
Background: The present study evaluated the diagnostic and prognostic value of biomarkers, including soluble forms of the receptor for advanced glycation end-products (s-RAGE), soluble urokinase plasminogen activator receptor (SuPAR), and others, for the occurrence of early-onset acute kidney injury (EO-AKI), EO-AKI non-recovery, day-90 major adverse kidney events (MAKE-90), and day-90 mortality in critically ill patients with Coronavirus Disease-19 (Covid-19).
Methods: A single-center, prospective study was conducted at the University Hospital of Clermont-Ferrand, France, between March 2020 and February 2021. The study included adult patients suffering from severe pneumonia caused by the SARS-CoV-2 virus, who were admitted to the hospital's intensive care unit.
Long-term renal consequences of COVID-19. Emerging evidence and unanswered questions.
Int Urol Nephrol
June 2025
Medizinische Klinik und Poliklinik IV, Klinikum der LMU München, Munich, Germany.
Purpose: COVID-19 infection is associated with a high burden of acute or acute on chronic kidney injury (AKI), particularly in critically ill patients. Given the large numbers of COVID-19 survivors, characterization of long-term adverse kidney effects of COVID-19 have important implications for post-COVID-19 care.
Methods: This narrative review provides a summary of epidemiologic evidence for post-COVID kidney disorders.
Prevalence and predictors of long COVID at 1 year in a cohort of hospitalized patients: A multicentric qualitative and quantitative study.
PLoS One
April 2025
Department of Medicine-III, Christian Medical College, Vellore, Tamil Nadu, India.
Introduction: According to WHO long COVID is defined as a continuation or development of new symptoms 3 months after the initial SARS-CoV-2 infection, with these symptoms lasting for at least 2 months with no other explanation. We followed up patients after an episode of acute COVID-19 for 1 year after hospital discharge from different parts of India.
Methods: This was a multi-centric study among patients ≥18 years hospitalized with COVID-19, which recruited patients at 6 weeks after hospital discharge (baseline).
Seroepidemiology and Risk Factors of in Iranian COVID-19 Patients: A Case-Control Study.
Iran J Parasitol
January 2025
Vice-Chancellery of Treatment, Imam Hasan Hospital, Alborz University of Medical Sciences, Karaj, Iran.
Background: Theoretically, there is a possible association between emerging SARS-CoV-2 infection and parasites such as . We aimed to evaluate the seroepidemiology of in COVID-19 patients and the control group as well as its correlation with risk factors.
Methods: Totally, 450 sera samples were taken from COVID-19 positive patients and controls from the Tehran, Karaj, and Shiraz cities, Iran.
Is joint hypermobility linked to self-reported non-recovery from COVID-19? Case-control evidence from the British COVID Symptom Study Biobank.
BMJ Public Health
June 2024
Department of Clinical and Experimental Medicine, Brighton and Sussex Medical School, Brighton, UK.
Objectives: This study sought to explore whether generalised joint hypermobility (GJH, a common marker of variant connective tissue) was a risk factor for self-reported non-recovery from COVID-19 infection.
Design: Prospective observational study.
Setting: COVID Symptom Study Biobank (https://cssbiobank.